1. Home
  2. IOVA vs SLNO Comparison

IOVA vs SLNO Comparison

Compare IOVA & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.75

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Soleno Therapeutics Inc.

SLNO

Soleno Therapeutics Inc.

HOLD

Current Price

$52.61

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOVA
SLNO
Founded
2007
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
2.3B
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
IOVA
SLNO
Price
$3.75
$52.61
Analyst Decision
Buy
Buy
Analyst Count
10
9
Target Price
$9.00
$90.13
AVG Volume (30 Days)
13.1M
5.8M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
14.84
108.90
EPS
N/A
0.39
Revenue
N/A
$1,450,788.00
Revenue This Year
$51.55
$151.77
Revenue Next Year
$37.55
$53.58
P/E Ratio
N/A
$134.83
Revenue Growth
N/A
138.82
52 Week Low
$1.64
$29.43
52 Week High
$5.63
$89.12

Technical Indicators

Market Signals
Indicator
IOVA
SLNO
Relative Strength Index (RSI) 52.44 77.37
Support Level $2.02 $48.91
Resistance Level $4.34 $55.47
Average True Range (ATR) 0.30 1.27
MACD 0.02 1.44
Stochastic Oscillator 51.69 99.63

Price Performance

Historical Comparison
IOVA
SLNO

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Share on Social Networks: